ArticleFrontiers in health services2026
Costs of breast cancer care by stage and HER-2 Status: a population-based study.
Article in Frontiers in health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer (BC) is one of the most common and leading causes of cancer-related deaths among women. Cost analysis of BC treatment provides essential information for health policy planning, including resource allocation. This study aims to present real-world data on the cost components of BC care, categorized by cancer stage and HER2 status. Methods: This retrospective, population-based cohort study examined 1,232 new BC cases diagnosed in 2021 across three Local Health Units in the Italian northeastern Veneto Region. The study calculated per-patient costs for all three years following BC incidence. Care costs were categorized by items and analyzed by cancer stage and HER2 BC status. Results: Over a three-year post-diagnosis period, care costs increased from € 25,630 to € 90,924. Total hospitalization costs increased from €6,500 in stage I to €15,488 in stage IV, with a ratio of 2.4. Outpatient costs increased from €11,143 to €25,296, with a ratio of 2.3. In-hospital drug administration rose from €4,427 to €34,210, with a ratio of 7.7. Across all stages, the mean overall cost increased from €27,817€ in HER2-negative patients to €52,193€ in HER2-positive patients, while the breast cancer-specific cost increased from €17,881€ to €36,564€, respectively. HER2-positive cancers incurred almost twice the cost of HER2-negative BC. Conclusions: The overall cost of BC care increases with the stage of cancer at diagnosis, which also affects the allocation of costs among various cost components. In the early stages, expenses mainly relate to surgical and outpatient procedures. For more advanced BC, care costs rise substantially, mainly due to systemic therapies and hospital-based care. The HER status at cancer presentation significantly impacts care costs across all cancer stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.